Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Advanced Proteome Therapeutics Corporation APTCF


Primary Symbol: V.APC.H

Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.

TSXV:APC.H - Post Discussion

Advanced Proteome Therapeutics Corporation > complicated news release
View:
Post by unionbroker on May 29, 2020 11:12am

complicated news release

APCs news releases tend to be very complex . Take time to actually read the news and you will be surprised by the magnitude of what they have accomplished.
Comment by austrochris on Jun 01, 2020 11:18am
Reading between the lines makes me more and more sure that this simply fantastic . 
Comment by Zorglub on Jun 01, 2020 11:32am
I least some activies on this stock. It was a sleeping beauty for a while...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities